Search results
Results From The WOW.Com Content Network
(Reuters) -The U.S. Senate's homeland security committee voted on Wednesday to approve a bill that could restrict business with Chinese biotech companies like BGI and WuXi AppTec on national ...
A newly minted biopharma initial public offering (IPO) has Wall Street analysts rushing to the gates to price it for massive gains.. Artiva Biotherapeutics (NASDAQ: ARTV) is making waves with its ...
Bipartisan bills introduced in Congress Thursday would effectively ban a Chinese genomics firm from doing business in America. Intel officials have warned China is grabbing U.S. genetic info.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise ...
(Reuters) -The U.S. House of Representatives committee on China has asked the FBI and the intelligence community for a briefing on GenScript Biotechnology Co and three subsidiaries to determine if ...
Geron Corporation has sponsored human clinical trials of several potential anti-cancer products. Imetelstat (GRN163L) is a drug that targets telomerase. [13] In studies conducted at Johns Hopkins University, GRN163L was active against both CD138+ and CD138neg cancer stem cells and eliminated the colony forming potential of both by five weeks. [14]